Targeted therapies and diabetes
| Affiliation auteurs | !!!! Error affiliation !!!! |
| Titre | Targeted therapies and diabetes |
| Type de publication | Journal Article |
| Year of Publication | 2017 |
| Auteurs | Verges B |
| Journal | CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION |
| Volume | 21 |
| Pagination | 66-69 |
| Date Published | MAR-APR |
| Type of Article | Article |
| ISSN | 2100-9619 |
| Mots-clés | diabetes, mTOR inhibitor, Targeted therapy, Tyrosine kinase inhibitor |
| Résumé | mTOR inhibitors, which are important anti-cancer agents, may frequently induce hyperglycemias in 13% to 50% of the patients. Diabetes induced by mTOR inhibitors seems to be due to both insulin resistance and reduced insulin secretion. Because of the high risk of diabetes with mTOR inhibitors, blood glucose needs to be carefully monitored during treatment. Tyrosine kinase inhibitors may induce both hyperglycemias and hypoglycemias |